35504-91-7

Upstream product

• 141-82-2 malonic acid 
• 6890-77-3 3-nitrophenylglyoxal 
• 17812-07-6 Benzoylacrylic acid 
• 298-12-4 Glyoxilic acid 
• 121-89-1 3-Nitroacetophenone 

Downstream Products

• 134949-95-4 (E)-5,5'-bis-(3-nitro-phenyl)-[3,3']bifurylidene-2,2'-dione 
• 813430-46-5 methyl (4R,5R)-5-methoxy-4-[(E)-4-(3-nitrophenyl)-4-oxobut-2-enoyloxy]-4,5-dihydrofuran-2-carboxylate 
• 871566-12-0 {[(2R,2aR,4aR,6R,7aS,7bS)-6-(3-Amino-phenyl)-2-methoxy-4-oxo-hexahydro-1,3,7-trioxa-cyclopenta[cd]indene-7a-carbonyl]-amino}-acetic acid 
• 871566-11-9 {[(2R,2aR,4aR,7aS,7bS)-2-Methoxy-6-(3-nitro-phenyl)-4-oxo-2a,4,4a,7b-tetrahydro-2H-1,3,7-trioxa-cyclopenta[cd]indene-7a-carbonyl]-amino}-acetic acid benzyl ester 
• 813430-70-5 methyl (2R,2aR,4aR,7aS,7bS)-6-(3-aminophenyl)-2-methoxy-4-oxo-2a,4,4a,7b-tetrahydro-2H-1,3,7-trioxacyclopenta[cd]indene-7a-carboxylate 
• 813430-68-1 (2R,2aR,4aR,6R,7aS,7bS)-6-(3-Amino-phenyl)-2-methoxy-4-oxo-hexahydro-1,3,7-trioxa-cyclopenta[cd]indene-7a-carboxylic acid methyl ester 
• 813430-53-4 methyl (2R,2aR,4aR,7aS,7bS)-6-(3-nitrophenyl)-2-methoxy-4-oxo-2a,4,4a,7b-tetrahydro-2H-1,3,7-trioxacyclopenta[cd]indene-7a-carboxylate 
• 1415480-52-2 C₁₈H₁₈N₂O₆ 

Relevant academic research and scientific papers

Design, synthesis, and bioevaluation of a novel class of (E)-4-oxo-crotonamide derivatives as potent antituberculosis agents

A series of novel (E)-4-oxo-2-crotonamide derivatives were designed and synthesized to find potent antituberculosis agents. All the target compounds were evaluated for their in vitro activity against Mycobacterium tuberculosis H37Rv(MTB). Results reveal that 4-phenyl moiety at part A and short methyl group at part C were found to be favorable. Most of the derivatives displayed promising activity against MTB with MIC ranging from 0.125 to 4 μg/mL. Especially, compound IIIa16 was found to have the best activity with MIC of 0.125 μg/mL against MTB and with MIC in the range of 0.05–0.48 μg/mL against drug-resistant clinical MTB isolates.

Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof

The present invention relates to compounds of general formula [in-line-formulae]R—Z1—Z2—Z3—R1, ??(I)[/in-line-formulae] wherein R, R1 and Z1 to Z3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Elaboration of D-(-)-ribose into a tricyclic, natural product-like scaffold

The construction of natural product-like, tricyclic compounds is reported. Starting from a D-(-)-ribose-derived dihydrofurane, the tricyclic scaffold is prepared via an intramolecular hetero-Diels-Alder reaction. The reaction proceeds with very high diast

4-phenyl-4-oxo-2-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity

PCT No. PCT/EP96/04517 Sec. 371 Date May 4, 1998 Sec. 102(e) Date May 4, 1998 PCT Filed Oct. 16, 1996 PCT Pub. No. WO97/17316 PCT Pub. Date May 15, 19974-Phenyl-4-oxo-butenoic acid derivatives for use in the treatment of the human or animal body by therapy; particularly as kynurenine-3-hydroxylase inhibitors, in the prevention and/or treatment of a neurodegenerative disease wherein the inhibition of such an enzyme is needed. The present invention further comprises a selected class of the above mentioned 4-phenyl-4-oxo-butenoic acid derivatives, their pharmaceutically acceptable salts, a process for their preparation and pharmaceutical compositions containing them.

3-(Benzoyl)oxiranecarboxamides

Novel trans-isomers of 3-(benzoyl)oxiranecarboxamides, useful as lipogenesis inhibitors in warm-blooded animals.

Method of inhibiting lipogensis with 3-(benzoyl)oxiranecarboxamides

Novel trans-isomers of 3-(benzoyl)oxiranecarboxamides, useful as lipogenesis inhibitors in warm-blooded animals. SP This application is a continuation-in-part of application Ser. No. 778,536, filed on Mar. 17, 1977, now U.S. Pat. No. 4,091,221.